Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880231 | 1.00 | MAPT (0.39) | MAPTTHRBNPC1LMNARAB9A | |
| SCHEMBL8125926 | 0.88 | F10 (0.41) | MAPTTHRBNPC1LMNARAB9A | |
| SCHEMBL13377663 | 0.81 | KEAP1 (0.35) | MAPTTHRBF10TP53CYP1A2 | |
| SCHEMBL9068511 | 0.79 | TP53 (0.35) | MAPTTHRBF10TP53CYP1A2 | |
| SCHEMBL432928 | 0.78 | GRM5 (0.43) | MAPTTHRBLMNAF10HTR1A | |
| SCHEMBL2627044 | 0.76 | MEN1 (0.38) | MAPTRAB9ASMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL20085592 | 0.76 | MAPT (0.41) | MAPTTHRBNPC1LMNARAB9A | |
| SCHEMBL30880233 | 0.76 | MAPT (0.41) | MAPTTHRBNPC1LMNARAB9A | |
| SCHEMBL13383468 | 0.75 | PIK3CD (0.38) | MAPTTHRBSMN1; SMN2F10CYP1A2 | |
| SCHEMBL87094 | 0.73 | F10 (0.39) | MAPTNPC1RAB9ASMN1; SMN2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| CN-1625400-A | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC (US) | 2005-06-08 | — | — | CN | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | MAPT 4330/4885THRB 1992/4885NPC1 4203/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | MAPT 4733/4885THRB 2525/4885NPC1 2426/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | MAPT 4391/4885THRB 1914/4885NPC1 2094/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885THRB 2000/4885NPC1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.